[Surgical treatment for advanced gastric cancer]

Feng Lin1, Wu-lin Wu

  • 1Department of Gastrointestinal Surgery, Guangdong Provincial Hospital, Guangzhou 510080, China. sylf3133@21cn.com

Insights

Gastric cancer remains a major global health threat. While surgery with D2 lymph node dissection is standard for advanced cases, neoadjuvant chemotherapy shows promise, requiring further large-scale studies for confirmation.

Area of Science:

  • Oncology
  • Surgical Oncology
  • Gastroenterology

Background:

  • Gastric cancer is a leading cause of cancer death globally, despite declining incidence.
  • Surgery, particularly with D2 lymph node dissection, is the primary treatment for advanced gastric cancer.
  • Lymph node metastasis and recurrence are significant challenges in gastric cancer management.

Discussion:

  • D2 lymph node dissection is the established standard surgical approach for advanced gastric cancer worldwide.
  • Neoadjuvant chemotherapy is being investigated as a potentially beneficial treatment strategy.
  • Clinical trials suggest positive outcomes for neoadjuvant chemotherapy in advanced gastric cancer patients.

Key Insights:

  • The importance of lymph node dissection in gastric cancer surgery is well-recognized.
  • Neoadjuvant chemotherapy is emerging as a promising therapeutic option for advanced gastric cancer.
  • Standardization of D2 lymph node dissection is crucial for effective surgical management.

Outlook:

  • Further large-scale randomized controlled studies are essential to validate the efficacy of neoadjuvant chemotherapy.
  • Continued research into optimizing surgical techniques and neoadjuvant therapies is needed.
  • Improving survival rates for gastric cancer patients remains a critical goal in oncology.